The developer of the AI ​​model Claude made an unusual acquisition: a biotech company with only one person, who used a chatbot to coordinate work with 11 laboratories and bring a treatment for a rare muscular dystrophy to encouraging results in mice within 18 months • Now the entrepreneur is joining the company, in what becomes its first internal drug development program